Upstream Bio (NASDAQ:UPB) Price Target Raised to $9.00

Upstream Bio (NASDAQ:UPB) had its price target upped by investment analysts at JPMorgan Chase & Co. from $8.00 to $9.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 29.22% from the stock’s previous close.

Several other equities analysts have also commented on the company. Truist Financial lowered their target price on Upstream Bio to $25.00 and set a “buy” rating for the company in a report on Tuesday. Mizuho reduced their price objective on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a research note on Monday, August 3rd. Finally, HC Wainwright began coverage on Upstream Bio in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $29.67.

Upstream Bio Stock Performance

Shares of Upstream Bio stock traded up $0.06 during trading hours on Friday, reaching $6.96. The company’s stock had a trading volume of 176,117 shares, compared to its average volume of 875,161. Upstream Bio has a one year low of $5.85 and a one year high of $33.68. The company’s 50 day simple moving average is $6.80 and its 200 day simple moving average is $9.92. The stock has a market cap of $381.47 million, a P/E ratio of -2.39 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 45.92%. On average, sell-side analysts predict that Upstream Bio will post -2.87 earnings per share for the current fiscal year.

Institutional Trading of Upstream Bio

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in Upstream Bio during the 4th quarter worth $29,000. Torren Management LLC bought a new stake in shares of Upstream Bio during the fourth quarter valued at about $30,000. Persistent Asset Partners Ltd bought a new stake in shares of Upstream Bio during the second quarter valued at about $34,000. BNP Paribas Financial Markets lifted its holdings in Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after purchasing an additional 2,158 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.